Skip to content

Author

Z. Tsourti

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Brief Report: Characterization of the Potentially Actionable TP53 Y220C Mutation in Non-Small Cell Lung Cancer. A Multicenter, European Thoracic Oncology Platform Study.

INTRODUCTION The tumor suppressor TP53 is the most frequently mutated gene in human cancer, and drugs targeting specific mutant p53 proteins have been developed. Rezatapopt, which reactivates the Y220C p53 protein, was recently evaluated in the Phase I PYNNACLE trial in patients with solid tumors, with promising result...

M. Molina-Vila, Z. Tsourti, A. Stenzinger et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.